Photogen Buys Alliance’s Imagent To Build Cardiovascular Imaging Franchise
This article was originally published in The Gray Sheet
Executive Summary
Photogen Technologies' acquisition of Alliance Pharmaceutical's medical imaging assets provides a cardiovascular market entry at least three years ahead of the company's own internal R&D program
You may also be interested in...
Alliance Touts Imagent Synthetic Heart Imaging Agent As Easier To Store
Alliance Pharmaceutical Corp. will launch its Imagent ultrasound heart imaging agent at the American Society of Echocardiography meeting in Orlando June 9-12
Molecular Biosystems Acquisition Builds Alliance's Cardiac Imaging Portfolio
Alliance Pharmaceutical's acquisition of Molecular Biosystems, Inc. for $10.2 mil. in stock will expand its existing ultrasound cardiac imaging agent portfolio to include royalties for Optison.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.